CAMBRIDGE, Mass., May 17, 2017 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a leader in discovering and
development targeted kinase medicines for patients with genomically
defined diseases, today announced that new data from its ongoing
Phase 1 clinical trial evaluating BLU-285 for the treatment of
advanced gastrointestinal stromal tumors (GIST) will be presented
in an oral presentation at the 2017 American Society of Clinical
Oncology (ASCO) Annual Meeting in Chicago, Illinois, June
2-6, 2017.
Presentation Title: Clinical activity of BLU-285 in
advanced gastrointestinal stromal tumor (GIST)
Session Title: GIST: Imatinib and Beyond
Date & Time: Monday, June 5,
2017 from 2:03-2:15 p.m. CT
(3:03-3:15 p.m. ET)
Abstract Number: 11011
Location: E450ab (McCormick Place)
The accepted abstract is available online on ASCO's website at
http://am.asco.org.
Investor Event and Webcast Information
Blueprint Medicines will host an investor event on Monday, June 5, 2017 beginning at 6:00 p.m. CT (7:00 p.m.
ET) in Chicago to review
the updated clinical data presented at ASCO for BLU-285 in GIST.
The event will be webcast live and can be accessed under "Events
& Presentations" in the Investors section of the Company's
website at www.blueprintmedicines.com. A replay of the webcast will
be available approximately two hours after the event and will be
available for 30 days following the event.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of targeted
and potent kinase medicines to improve the lives of patients with
genomically defined diseases. Its approach is rooted in a deep
understanding of the genetic blueprint of cancer and other disease
driven by the abnormal activation of kinases. Blueprint medicines
is advancing four programs in clinical development for subsets of
patients with gastrointestinal stromal tumors, hepatocellular
carcinoma, systemic mastocytosis, non-small cell lung cancer,
medullary thyroid cancer and other advanced solid tumors, as well
as multiple programs in research and preclinical development. For
more information, please visit www.blueprintmedicines.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-new-data-from-ongoing-phase-1-clinical-trial-of-blu-285-in-patients-with-advanced-gastrointestinal-stromal-tumors-at-2017-asco-annual-meeting-300459506.html
SOURCE Blueprint Medicines